Allergic asthma: An indication for allergen immunotherapy

Allergen immunotherapy (AIT) as a vali-dated, disease-modifying treatment is now-adays a widely recommended therapy op-tion for allergic rhinitis and allergic asthma. The registration of allergen extracts used for AIT is based on allergen standardiza-tion, dose finding trials, and phase 3 trials proving their efficacy in high-quality, statistically significant randomized clinical trials. Real-world evidence (RWE) studies confirm the clinical relevance of these findings. The most data are available for the treatment of patients suffering from allergic rhinitis. Due to the similar inflammatory mechanisms, allergic rhinitis is often associated with al-lergic asthma. AIT, which induces tolerance against individual allergens, is the approach to treat the underlying mechanisms of these two interrelated respiratory diseases. Some trials have been published focusing primar-ily on the effect of AIT on parameters of al-lergic asthma. Here we give a summary of the evidence for the efficacy of AIT in the indication of allergic asthma.